Press Releases

Press Releases

Jun 07, 2022
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
Jun 01, 2022
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
May 09, 2022
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
May 05, 2022
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
Apr 20, 2022
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
Apr 11, 2022
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
Apr 08, 2022
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
Mar 08, 2022
Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting
Mar 07, 2022
Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress
Mar 01, 2022
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Displaying 1 - 10 of 14
Media & IR Contact
Investor Contact

Kimberly Minarovich
Argot Partners
[email protected]

Media Contact

David Rosen
Argot Partners
[email protected]

Helpful Tools